Comparative Pharmacology
Head-to-head clinical analysis: AXID AR versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID AR versus PEPCID RPD.
AXID AR vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nizatidine is a competitive, reversible inhibitor of histamine at the H2-receptors of the gastric parietal cells, reducing gastric acid secretion.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
75 mg orally once daily at bedtime for heartburn relief; maximum 150 mg per 24 hours.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours (mean ~2 hours) in patients with normal renal function. In elderly or those with creatinine clearance <50 mL/min, half-life may extend to 4–6 hours, necessitating dose adjustment.
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Primarily renal; ~60% of an oral dose is excreted unchanged in urine via tubular secretion and glomerular filtration. Hepatic metabolism accounts for ~30% (N-oxidation, S-oxidation, and N-demethylation), with metabolites and small amounts of parent drug eliminated in feces via bile.
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist